Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Cell Therapeutics Acquires SMi; Gains Access to Oncologic Brostallicin, PGx Tools

Cell Therapeutics Acquires SMi; Gains Access to Oncologic Brostallicin, PGx Tools

Aug 15, 2007
Premium
Cell Therapeutics’ recent acquisition of Systems Medicine will not only garner CTI worldwide rights to brostallicin, a DNA minor-groove binding agent that has shown anti-tumor activity in various types of cancer, but will also enable CTI to leverage SMi’s affiliation with the Translational Genomics Research Institute to personalize treatment for brostallicin and other oncology drugs in their pipeline using PGx tools.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
24
Featured Webinar

New Insights Underscore the Need to Identify NTRK Fusions in Childhood Tumors

Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.

Oct
20
Featured Webinar

Crystal Digital PCR for Accurate Chimerism Monitoring after Stem Cell Transplantation

Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

Oct
22
Featured Webinar

Adoption of Broad NGS Profiling for HRR Deficiency: Looking Beyond BRCA, SNPs, and Indels

Sponsored by
Sophia Genetics

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs).

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.